An Analysis of Temozolomide-related Adverse Drug Reactions Reported to the Medicines and Healthcare Products Regulatory Agency Through the Yellow Card Scheme Aiming to Characterise Idiosyncratic Profound Bone marrow Suppression Tantamount to Aplastic Anaemia

S. Dixit; M. Hingorani; V. Allgar

doi:10.1016/j.clon.2013.10.003

An Analysis of Temozolomide-related Adverse Drug Reactions Reported to the Medicines and Healthcare Products Regulatory Agency Through the Yellow Card Scheme Aiming to Characterise Idiosyncratic Profound Bone marrow Suppression Tantamount to Aplastic Anaemia

S. Dixit, M. Hingorani, V. Allgar

Peninsula Medical School

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	120-121
Number of pages	0
Journal	Clinical Oncology
Volume	26
Issue number	2
DOIs	https://doi.org/10.1016/j.clon.2013.10.003
Publication status	Published - Feb 2014

Access to Document

10.1016/j.clon.2013.10.003

Cite this

Dixit, S., Hingorani, M., & Allgar, V. (2014). An Analysis of Temozolomide-related Adverse Drug Reactions Reported to the Medicines and Healthcare Products Regulatory Agency Through the Yellow Card Scheme Aiming to Characterise Idiosyncratic Profound Bone marrow Suppression Tantamount to Aplastic Anaemia. Clinical Oncology, 26(2), 120-121. https://doi.org/10.1016/j.clon.2013.10.003

@article{5076e76268f144e78391ecb317cea3ef,

title = "An Analysis of Temozolomide-related Adverse Drug Reactions Reported to the Medicines and Healthcare Products Regulatory Agency Through the Yellow Card Scheme Aiming to Characterise Idiosyncratic Profound Bone marrow Suppression Tantamount to Aplastic Anaemia",

author = "S. Dixit and M. Hingorani and V. Allgar",

year = "2014",

month = feb,

doi = "10.1016/j.clon.2013.10.003",

language = "English",

volume = "26",

pages = "120--121",

journal = "Clinical Oncology",

issn = "0936-6555",

publisher = "W.B. Saunders Ltd",

number = "2",

}

Dixit, S, Hingorani, M & Allgar, V 2014, 'An Analysis of Temozolomide-related Adverse Drug Reactions Reported to the Medicines and Healthcare Products Regulatory Agency Through the Yellow Card Scheme Aiming to Characterise Idiosyncratic Profound Bone marrow Suppression Tantamount to Aplastic Anaemia', Clinical Oncology, vol. 26, no. 2, pp. 120-121. https://doi.org/10.1016/j.clon.2013.10.003

An Analysis of Temozolomide-related Adverse Drug Reactions Reported to the Medicines and Healthcare Products Regulatory Agency Through the Yellow Card Scheme Aiming to Characterise Idiosyncratic Profound Bone marrow Suppression Tantamount to Aplastic Anaemia. / Dixit, S.; Hingorani, M.; Allgar, V.
In: Clinical Oncology, Vol. 26, No. 2, 02.2014, p. 120-121.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - An Analysis of Temozolomide-related Adverse Drug Reactions Reported to the Medicines and Healthcare Products Regulatory Agency Through the Yellow Card Scheme Aiming to Characterise Idiosyncratic Profound Bone marrow Suppression Tantamount to Aplastic Anaemia

AU - Dixit, S.

AU - Hingorani, M.

AU - Allgar, V.

PY - 2014/2

Y1 - 2014/2

U2 - 10.1016/j.clon.2013.10.003

DO - 10.1016/j.clon.2013.10.003

M3 - Article

SN - 0936-6555

VL - 26

SP - 120

EP - 121

JO - Clinical Oncology

JF - Clinical Oncology

IS - 2

ER -